Press release
Epithelioid Sarcoma Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, NICE Approvals, Prevalence, Therapies and Companies by DelveInsight
Epithelioid Sarcoma Treatment Market
(Albany, USA) DelveInsight's "Epithelioid Sarcoma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Epithelioid Sarcoma, historical and forecasted epidemiology as well as the Epithelioid Sarcoma market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Epithelioid Sarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Epithelioid Sarcoma market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Epithelioid Sarcoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Epithelioid Sarcoma market.
To Know in detail about the Epithelioid Sarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epithelioid Sarcoma Market Forecast [https://www.delveinsight.com/report-store/epithelioid-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key facts of the Epithelioid Sarcoma Market Report:
* The Epithelioid Sarcoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In April 2025, Epizyme announced results of a Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
* In November 2024, Haihe Biopharma Co., Ltd announced results of a Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of HH2853 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors
* As per the estimation of DelveInsight, there were 68 cases of ES in 2021, in the US, which was 37% of overall cases of 7MM
* According to DelveInsight's estimation, 68 occurrences of ES, or 37% of all cases of 7MM, were reported in the US in 2021
* Germany reported the most ES cases among the EU-5 in 2021 (24 cases), followed by Italy (21 instances) and France (20). Spain has the fewest cases (13 cases)
* Epithelioid sarcomas are uncommon, accounting for fewer than 1% of soft tissue sarcomas, and exhibit a preference for men (up to a 2:1 male to female ratio), according to Needs et al. (2022). The majority of reported tumours affect young boys between the ages of 10 and 45. With a median age of 27, the range of ages includes 4 to 90
* Key Epithelioid Sarcoma Companies: Epizyme, Eli Lilly and Company, Pfizer, Merck Sharp & Dohme, GlaxoSmithKline and Among Others
* Key Epithelioid Sarcoma Therapies: Tazemetostat in Combination With Doxorubicin, Doxorubicin HCl, Talimogene Laherparepvec (T-VEC), and others
* The Epithelioid Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epithelioid Sarcoma pipeline products will significantly revolutionize the Epithelioid Sarcoma market dynamics.
Epithelioid Sarcoma Overview
Epithelioid sarcoma is a rare and aggressive type of soft tissue cancer that most commonly affects young adults. Epithelioid sarcoma typically begins as a slow-growing lump under the skin, often in the extremities such as the hands, forearms, or feet, but can also occur in the trunk and other deep soft tissues. Epithelioid sarcoma is characterized by its tendency to recur locally and its potential to spread to lymph nodes and distant organs, particularly the lungs.
Epithelioid sarcoma diagnosis involves a combination of imaging studies and a biopsy, followed by immunohistochemistry to distinguish it from other tumors. Epithelioid sarcoma is often misdiagnosed due to its resemblance to benign conditions. Epithelioid sarcoma treatment typically includes surgical resection with wide margins, but radiation therapy and chemotherapy may also be recommended based on the tumor's stage and location.
Epithelioid sarcoma has limited treatment options, but recent advancements include targeted therapies and clinical trials exploring novel agents. Epithelioid sarcoma patients often require long-term monitoring due to high recurrence rates. Epithelioid sarcoma awareness and research funding are crucial for improving outcomes and developing new therapies. Epithelioid sarcoma prognosis varies based on early detection and comprehensive treatment strategies.
Get a Free sample for the Epithelioid Sarcoma Market Report: Epithelioid Sarcoma Treatment Market [https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Epithelioid Sarcoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Epithelioid Sarcoma Epidemiology Segmentation:
The Epithelioid Sarcoma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
* Total Prevalence of Epithelioid Sarcoma
* Prevalent Cases of Epithelioid Sarcoma by severity
* Gender-specific Prevalence of Epithelioid Sarcoma
* Diagnosed Cases of Episodic and Chronic Epithelioid Sarcoma
Download the report to understand which factors are driving Epithelioid Sarcoma epidemiology trends @ Epithelioid Sarcoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Epithelioid Sarcoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epithelioid Sarcoma market or expected to get launched during the study period. The analysis covers Epithelioid Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Epithelioid Sarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Epithelioid Sarcoma Therapies and Key Companies
* Tazemetostat in Combination With Doxorubicin: Epizyme, Inc.
* Doxorubicin HCl: Ipsen
* Talimogene Laherparepvec (T-VEC): Amgen
Discover more about therapies set to grab major Epithelioid Sarcoma market share @ Epithelioid Sarcoma Treatment Market [https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Epithelioid Sarcoma Market Report
* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Epithelioid Sarcoma Companies: Epizyme, Inc., Ipsen, Amgen, and others
* Key Epithelioid Sarcoma Therapies: Tazemetostat in Combination With Doxorubicin, Doxorubicin HCl, Talimogene Laherparepvec (T-VEC), and others
* Epithelioid Sarcoma Therapeutic Assessment: Epithelioid Sarcoma current marketed and Epithelioid Sarcoma emerging therapies
* Epithelioid Sarcoma Market Dynamics: Epithelioid Sarcoma market drivers and Epithelioid Sarcoma market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Epithelioid Sarcoma Unmet Needs, KOL's views, Analyst's views, Epithelioid Sarcoma Market Access and Reimbursement
To know more about Epithelioid Sarcoma companies working in the treatment market, visit @ Epithelioid Sarcoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Epithelioid Sarcoma Market Report Introduction
2. Executive Summary for Epithelioid Sarcoma
3. SWOT analysis of Epithelioid Sarcoma
4. Epithelioid Sarcoma Patient Share (%) Overview at a Glance
5. Epithelioid Sarcoma Market Overview at a Glance
6. Epithelioid Sarcoma Disease Background and Overview
7. Epithelioid Sarcoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Epithelioid Sarcoma
9. Epithelioid Sarcoma Current Treatment and Medical Practices
10. Epithelioid Sarcoma Unmet Needs
11. Epithelioid Sarcoma Emerging Therapies
12. Epithelioid Sarcoma Market Outlook
13. Country-Wise Epithelioid Sarcoma Market Analysis (2019-2032)
14. Epithelioid Sarcoma Market Access and Reimbursement of Therapies
15. Epithelioid Sarcoma Market Drivers
16. Epithelioid Sarcoma Market Barriers
17. Epithelioid Sarcoma Appendix
18. Epithelioid Sarcoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epithelioid-sarcoma-treatment-market-2032-ema-pdma-fda-approval-clinical-trials-medication-epidemiology-nice-approvals-prevalence-therapies-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epithelioid Sarcoma Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, NICE Approvals, Prevalence, Therapies and Companies by DelveInsight here
News-ID: 3994587 • Views: …
More Releases from ABNewswire
Idiopathic Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.
The…
Global Sound Reinforcement Market Set to Grow at 4.28% CAGR, Reaching USD 38.58 …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030.
The global sound reinforcement market [https://www.arizton.com/market-reports/sound-reinforcement-market-size-growth] is projected to expand from USD 30 billion in 2024 to USD 38.58 billion by 2030, growing at a steady 4.28% CAGR, according to Arizton. This growth is being driven by rising demand for high-quality audio solutions across live events and entertainment venues. Advances in audio technology have significantly enhanced…
Gelt Raises $13M Series A to Expand AI-Powered Tax Solutions for Real Estate Inv …
Miami, FL - September 30, 2025 - Gelt [https://www.joingelt.com/], the first AI-native tax firm for investors and the Top 1% in the U.S., today announced it has raised $13 million in Series A [https://www.businesswire.com/news/home/20250930325477/en/Gelt-the-First-AI-Native-Tax-Firm-Raises-%2413M-in-Series-A-Funding-to-Transform-Tax-Strategy-Into-Year-Round-Wealth-Optimization], bringing its total funding to $21.2 million. Global investors, Zvi Limon of the Rimon Group, Vintage Investment Partners, and TLV Partners led the funding. As part of the launch, Yoram Tietz, former Managing Partner at EY…
Applications of 5-50mm security camera lens
The application scenarios of 5-50 mm surveillance lenses are primarily categorized according to the variations in field of view resulting from changes in focal length. The specific applications are as follows:
1. Wide-angle range (5-12 mm)
Panoramic monitoring for confined spaces A focal length of 5-8 mm (with a field of view of 60 degrees -90 degrees ) is suitable for enclosed small areas within 5 times 5 meters, such as elevator…
More Releases for Epithelioid
Epithelioid Sarcoma Market is expected to reach USD 1.2 billion by 2034
Epithelioid sarcoma is a rare and aggressive form of soft tissue sarcoma that typically affects young adults and adolescents. Despite being classified as a soft tissue cancer, it is notorious for its high recurrence rate and metastasis, often posing challenges in treatment and long-term survival. Standard therapies such as surgical resection and chemotherapy have been the mainstay, but recent advances in targeted therapies, immunotherapies, and rare disease research incentives are…
Perivascular Epithelioid Cell Tumor Market Size, Share and Growth Report, 2034
Introduction
Perivascular epithelioid cell tumors (PEComas) are a rare group of tumors characterized by the presence of epithelioid cells and smooth muscle components. These tumors can arise in various organs, including the lungs, kidneys, liver, and soft tissues, and are often classified as benign or malignant based on their characteristics. While PEComas are uncommon, they present unique challenges for diagnosis and treatment due to their heterogeneous nature. The tumors can exhibit…
Epithelioid Sarcoma Market Future Business Opportunities 2025-2032 | Epizyme, El …
The epithelioid sarcoma market is estimated to be valued at USD 1.57 Bn in 2025 and is expected to reach USD 2.93 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.3% from 2025 to 2032.
According to the latest research from CoherentMI, the Epithelioid Sarcoma Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough…
Epithelioid Sarcoma Treatment: Advancements and Emerging Trends in Rare Cancer C …
Epithelioid sarcoma is a rare type of soft tissue cancer that primarily affects young adults and tends to appear in the extremities, such as hands and arms. This cancer type is known for its challenging diagnosis, high recurrence rate, and complex treatment requirements. Because epithelioid sarcoma is a rare and aggressive form of cancer, its treatment landscape has evolved rapidly in recent years, bringing new therapies and approaches to patients.…
Epithelioid Sarcoma Treatment Market: A Comprehensive Overview
1. Introduction
Epithelioid sarcoma (ES) is a rare and aggressive soft tissue sarcoma, predominantly affecting young adults. It has a propensity for recurrence and metastasis, often posing significant challenges for effective treatment. The complexities surrounding epithelioid sarcoma have driven innovations in the treatment landscape, sparking considerable growth and evolution in the global market for ES therapies. The global epithelioid sarcoma treatment market is shaped by several factors including advancements in therapeutic…
Epithelioid Sarcoma Treatment Market Booming Worldwide With Leading Key Players …
The global Epithelioid Sarcoma Treatment Market was valued at $1.32 billion in 2023 and is projected to grow to $2.66 billion by 2031, with a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031.
DataM Intelligence has released a new research report on "Asia Latin America And Middle East Marine Generator Set Market Size 2024." This report offers in-depth insights into key factors such as regional growth, segmentation,…
